Personal information

Activities

Works (50 of 87)

Items per page:
Page 1 of 2

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies

Biomedicines
2024-12 | Journal article | Author
Contributors: Federica Malighetti; Matteo Villa; MARIO MAURI; Simone Piane; Valentina Crippa; Ilaria Crespiatico; Federica Cocito; Elisa Bossi; Carolina Steidl; Ivan Civettini et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Comportamiento de la proteína antiapoptótica BCL2 en modelos celulares de cáncer de pulmón de células no pequeñas frente a tratamientos con inhibidores ALK y su potencial inhibición dual BCL2-ALK

Horizonte Médico (Lima)
2024-09-17 | Journal article
Contributors: Richard Zapata-Dongo; Diletta Fontana; Luca Mologni; Juan Faya-Castillo; Francesca Silva-Torres; Brenda Moy Diaz; Stefany Infante Varillas
Source: check_circle
Crossref

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Leukemia
2024-08 | Journal article
Contributors: Diletta Fontana; Federica Malighetti; Matteo Villa; Alfonso Zambon; Carlo Gambacorti-Passerini; Luca Mologni
Source: check_circle
Crossref

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells

International Journal of Molecular Sciences
2023-11 | Journal article | Author
Contributors: Nicoletta Cordani; Luca Mologni; Piazza Rocco; Pietro Tettamanti; Viola Cogliati; MARIO MAURI; Matteo Villa; Federica Malighetti; Camillo Di Bella; Marta Jaconi et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering

Computers in Biology and Medicine
2023-08 | Journal article
Contributors: Valentina Crippa; Federica Malighetti; Matteo Villa; Alex Graudenzi; Rocco Piazza; Luca Mologni; Daniele Ramazzotti
Source: check_circle
Crossref

Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase

European Journal of Medicinal Chemistry
2022-08 | Journal article
Contributors: Luca Mologni; Alexandre Orsato; Alfonso Zambon; Sébastien Tardy; William H. Bisson; Cedric Schneider; Monica Ceccon; Michela Viltadi; Joseph D'Attoma; Sara Pannilunghi et al.
Source: check_circle
Crossref

Correction to “Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase”

ACS Omega
2022-06-28 | Journal article
Contributors: Luca Mologni; Sébastien Tardy; Alfonso Zambon; Alexandre Orsato; Cédric Schneider; William H. Bisson; Monica Ceccon; Michela Viltadi; David Goyard; Pierre Garcia et al.
Source: check_circle
Crossref

Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase

ACS Omega
2022-05-24 | Journal article
Contributors: Luca Mologni; Sébastien Tardy; Alfonso Zambon; Alexandre Orsato; William H. Bisson; Monica Ceccon; Michela Viltadi; Joseph D’Attoma; Sara Pannilunghi; Vito Vece et al.
Source: check_circle
Crossref

Dual kinase targeting in leukemia

Cancers
2021 | Journal article
EID:

2-s2.0-85100212431

Part of ISSN: 20726694
Contributors: Mologni, L.; Marzaro, G.; Redaelli, S.; Zambon, A.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer

Cancers
2021 | Journal article
EID:

2-s2.0-85117047988

Part of ISSN: 20726694
Contributors: Villa, M.; Sharma, G.G.; Manfroni, C.; Cortinovis, D.; Mologni, L.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome

Nature Communications
2021 | Journal article
EID:

2-s2.0-85109139228

Part of ISSN: 20411723
Contributors: Banfi, F.; Rubio, A.; Zaghi, M.; Massimino, L.; Fagnocchi, G.; Bellini, E.; Luoni, M.; Cancellieri, C.; Bagliani, A.; Di Resta, C. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

Leukemia
2021 | Journal article
EID:

2-s2.0-85096875485

Part of ISSN: 14765551 08876924
Contributors: Lobello, C.; Tichy, B.; Bystry, V.; Radova, L.; Filip, D.; Mraz, M.; Montes-Mojarro, I.-A.; Prokoph, N.; Larose, H.; Liang, H.-C. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma

Cancers
2021 | Journal article
EID:

2-s2.0-85114110721

Part of ISSN: 20726694
Contributors: Arosio, G.; Sharma, G.G.; Villa, M.; Mauri, M.; Crespiatico, I.; Fontana, D.; Manfroni, C.; Mastini, C.; Zappa, M.; Magistroni, V. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target

Haematologica
2021 | Journal article
EID:

2-s2.0-85107390696

Part of ISSN: 15928721 03906078
Contributors: Larose, H.; Prokoph, N.; Matthews, J.D.; Schlederer, M.; Högler, S.; Alsulami, A.F.; Ducray, S.P.; Nuglozeh, E.; Fazaludeen, M.F.; Elmouna, A. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization

Clinical Case Reports
2020 | Journal article
EID:

2-s2.0-85076118451

Part of ISSN: 20500904
Contributors: Crespiatico, I.; Bossi, E.; Brioschi, F.; Piazza, R.; Mologni, L.; Gambacorti-Passerini, C.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

IL10RA modulates crizotinib sensitivity in NPM1-ALK<sup>+</sup> anaplastic large cell lymphoma

Blood
2020 | Journal article
EID:

2-s2.0-85090428303

Part of ISSN: 15280020 00064971
Contributors: Prokoph, N.; Probst, N.A.; Lee, L.C.; Monahan, J.M.; Matthews, J.D.; Liang, H.-C.; Bahnsen, K.; Montes-Mojarro, I.A.; Karaca-Atabay, E.; Sharma, G.G. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia

HemaSphere
2020 | Journal article
EID:

2-s2.0-85100725387

Part of ISSN: 25729241
Contributors: Fontana, D.; Ramazzotti, D.; Aroldi, A.; Redaelli, S.; Magistroni, V.; Pirola, A.; Niro, A.; Massimino, L.; Mastini, C.; Brambilla, V. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy

American Journal of Hematology
2020-12 | Journal article
Contributors: Elisa Bossi; Andrea Aroldi; Filippo A. Brioschi; Carolina Steidl; Silvia Baretta; Rossella Renso; Luisa Verga; Diletta Fontana; Geeta G. Sharma; Luca Mologni et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib

Journal of Thoracic Oncology
2019 | Journal article
EID:

2-s2.0-85073991824

Part of ISSN: 15561380 15560864
Contributors: Sharma, G.G.; Cortinovis, D.; Agustoni, F.; Arosio, G.; Villa, M.; Cordani, N.; Bidoli, P.; Bisson, W.H.; Pagni, F.; Piazza, R. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

We shall overcome (drug resistance) some day

Oncotarget
2019 | Journal article
EID:

2-s2.0-85059580479

Part of ISSN: 19492553
Contributors: Sharma, G.G.; Mologni, L.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma

Nature Medicine
2019 | Journal article
EID:

2-s2.0-85058052832

Part of ISSN: 1546170X 10788956
Contributors: Menotti, M.; Ambrogio, C.; Cheong, T.-C.; Pighi, C.; Mota, I.; Cassel, S.H.; Compagno, M.; Wang, Q.; Dall’Olio, R.; Minero, V.G. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells

Neoplasia (United States)
2018 | Journal article
EID:

2-s2.0-85044573632

Part of ISSN: 14765586 15228002
Contributors: Mologni, L.; Costanza, M.; Sharma, G.G.; Viltadi, M.; Massimino, L.; Citterio, S.; Purgante, S.; Raman, H.; Pirola, A.; Zucchetti, M. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer

Cancer Research
2018 | Journal article
EID:

2-s2.0-85057064429

Part of ISSN: 15387445 00085472
Contributors: Redaelli, S.; Ceccon, M.; Zappa, M.; Sharma, G.G.; Mastini, C.; Mauri, M.; Nigoghossian, M.; Massimino, L.; Cordani, N.; Farina, F. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Mitochondrial hyperactivation and enhanced ROS production are involved in toxicity induced by oncogenic kinases over-signaling

Cancers
2018 | Journal article
EID:

2-s2.0-85058454587

Part of ISSN: 20726694
Contributors: Ceccon, M.; Mauri, M.; Massimino, L.; Giudici, G.; Piazza, R.; Gambacorti-Passerini, C.; Mologni, L.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier
grade
Preferred source (of 2)‎

Novel targeted therapeutics for MEN2

Endocrine-Related Cancer
2018 | Journal article
EID:

2-s2.0-85042613088

Part of ISSN: 14796821 13510088
Contributors: Redaelli, S.; Plaza-Menacho, I.; Mologni, L.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy

Oncogene
2018 | Journal article
EID:

2-s2.0-85044095990

Part of ISSN: 14765594 09509232
Contributors: Saponaro, C.; Sergio, S.; Coluccia, A.; De Luca, M.; La Regina, G.; Mologni, L.; Famiglini, V.; Naccarato, V.; Bonetti, D.; Gautier, C. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells

European Journal of Cancer
2018-11 | Journal article
Contributors: Luca Mologni
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

Cancers
2018-02-28 | Journal article
Contributors: Geeta Sharma; Ines Mota; Luca Mologni; Enrico Patrucco; Carlo Gambacorti-Passerini; Roberto Chiarle
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

Discovery of <sup>wt</sup>RET and <sup>V804M</sup>RET Inhibitors: From Hit to Lead

ChemMedChem
2017 | Journal article
EID:

2-s2.0-85028317517

Part of ISSN: 18607187 18607179
Contributors: Mologni, L.; Dalla Via, M.; Chilin, A.; Palumbo, M.; Marzaro, G.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer

Oncotarget
2017 | Journal article
EID:

2-s2.0-85032674139

Part of ISSN: 19492553
Contributors: Awad, M.M.; Mastini, C.; Blasco, R.B.; Mologni, L.; Voena, C.; Mussolin, L.; Mach, S.L.; Adeni, A.E.; Lydon, C.A.; Sholl, L.M. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

RET kinase inhibitors: a review of recent patents (2012–2015)

Expert Opinion on Therapeutic Patents
2017 | Journal article
EID:

2-s2.0-85004025692

Part of ISSN: 17447674 13543776
Contributors: Mologni, L.; Gambacorti-Passerini, C.; Goekjian, P.; Scapozza, L.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition

Journal of Cancer
2017 | Journal article
EID:

2-s2.0-85009786852

Part of ISSN: 18379664
Contributors: Mologni, L.; Magistroni, V.; Casuscelli, F.; Montemartini, M.; Gambacorti-Passerini, C.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients

American Journal of Hematology
2017-10 | Journal article
Contributors: Luca Mologni; Rocco Piazza; Praveen Khandelwal; Alessandra Pirola; Carlo Gambacorti‐Passerini
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications

Molecular Cancer Therapeutics
2016 | Journal article
EID:

2-s2.0-84964355641

Part of ISSN: 15388514 15357163
Contributors: Ardini, E.; Menichincheri, M.; Banfi, P.; Bosotti, R.; De Ponti, C.; Pulci, R.; Ballinari, D.; Ciomei, M.; Texido, G.; Degrassi, A. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency

Oncogene
2016 | Journal article
EID:

2-s2.0-84949921827

Part of ISSN: 14765594 09509232
Contributors: Ceccon, M.; Merlo, M.E.B.; Mologni, L.; Poggio, T.; Varesio, L.M.; Menotti, M.; Bombelli, S.; Rigolio, R.; Manazza, A.D.; Di Giacomo, F. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma

Oncotarget
2016 | Journal article
EID:

2-s2.0-84995735627

Part of ISSN: 19492553
Contributors: Redaelli, S.; Ceccon, M.; Antolini, L.; Rigolio, R.; Pirola, A.; Peronaci, M.; Gambacorti-Passerini, C.; Mologni, L.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK

Cancer Medicine
2015 | Journal article
EID:

2-s2.0-85006201986

Part of ISSN: 20457634
Contributors: Fontana, D.; Ceccon, M.; Gambacorti-Passerini, C.; Mologni, L.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Current and future treatment of anaplastic lymphoma kinase-rearranged cancer

World Journal of Clinical Oncology
2015 | Journal article
EID:

2-s2.0-84945122373

Part of ISSN: 22184333
Contributors: Mologni, L.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Efficacy of a cancer vaccine against ALK-rearranged lung tumors

Cancer Immunology Research
2015 | Journal article
EID:

2-s2.0-84961604584

Part of ISSN: 23266074 23266066
Contributors: Voena, C.; Menotti, M.; Mastini, C.; Di Giacomo, F.; Longo, D.L.; Castella, B.; Merlo, M.E.B.; Ambrogio, C.; Wang, Q.; Minero, V.G. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783))

Molecular Cancer Research
2015 | Journal article
EID:

2-s2.0-84945298906

Part of ISSN: 15573125 15417786
Contributors: Ceccon, M.; Mologni, L.; Giudici, G.; Piazza, R.; Pirola, A.; Fontana, D.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Expanding the portfolio of anti-ALK weapons

Translational Lung Cancer Research
2015 | Journal article
EID:

2-s2.0-84960087066

Part of ISSN: 22264477 22186751
Contributors: Mologni, L.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922

Oncotarget
2015 | Journal article
EID:

2-s2.0-84925645313

Part of ISSN: 19492553
Contributors: Mologni, L.; Ceccon, M.; Pirola, A.; Chiriano, G.; Piazza, R.; Scapozza, L.; Gambacorti-Passerini, C.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma

Molecular Cancer Research
2015 | Journal article
EID:

2-s2.0-84928036655

Part of ISSN: 15573125 15417786
Contributors: Ceccon, M.; Mologni, L.; Giudici, G.; Piazza, R.; Pirola, A.; Fontana, D.; Gambacorti-Passerini, C.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients

Journal of the National Cancer Institute
2014 | Journal article
EID:

2-s2.0-84897109567

Part of ISSN: 14602105 00278874
Contributors: Passerini, C.G.; Farina, F.; Stasia, A.; Redaelli, S.; Ceccon, M.; Mologni, L.; Messa, C.; Guerra, L.; Giudici, G.; Sala, E. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy

Cellular Signalling
2014 | Journal article
EID:

2-s2.0-84900006326

Part of ISSN: 18733913 08986568
Contributors: Plaza-Menacho, I.; Mologni, L.; McDonald, N.Q.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors

Bioorganic and Medicinal Chemistry
2014 | Journal article
EID:

2-s2.0-84893808625

Part of ISSN: 14643391 09680896
Contributors: Tardy, S.; Orsato, A.; Mologni, L.; Bisson, W.H.; Donadoni, C.; Gambacorti-Passerini, C.; Scapozza, L.; Gueyrard, D.; Goekjian, P.G.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors

Molecular Cancer Research
2013 | Journal article
EID:

2-s2.0-84874437000

Part of ISSN: 15417786 15573125
Contributors: Ceccon, M.; Mologni, L.; Bisson, W.; Scapozza, L.; Gambacorti-Passerini, C.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex

Neoplasia (United States)
2013 | Journal article
EID:

2-s2.0-84877057244

Part of ISSN: 14765586 15228002
Contributors: Piazza, R.; Magistroni, V.; Mogavero, A.; Andreoni, F.; Ambrogio, C.; Chiarle, R.; Mologni, L.; Bachmann, P.S.; Lock, R.B.; Collini, P. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase

Molecular and Cellular Endocrinology
2013 | Journal article
EID:

2-s2.0-84880361411

Part of ISSN: 03037207 18728057
Contributors: Mologni, L.; Redaelli, S.; Morandi, A.; Plaza-Menacho, I.; Gambacorti-Passerini, C.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Nature Genetics
2013 | Journal article
EID:

2-s2.0-84871988651

Part of ISSN: 10614036 15461718
Contributors: Piazza, R.; Valletta, S.; Winkelmann, N.; Redaelli, S.; Spinelli, R.; Pirola, A.; Antolini, L.; Mologni, L.; Donadoni, C.; Papaemmanuil, E. et al.
Source: Self-asserted source
Luca Mologni via Scopus - Elsevier
Items per page:
Page 1 of 2

Peer review (3 reviews for 3 publications/grants)

Review activity for Cell death discovery. (1)
Review activity for iScience. (1)
Review activity for Signal transduction and targeted therapy. (1)